Biosimilar Launch Considerations Highlight SPT Week in Review

5. Hemophilia A Drug Reduces Number of Bleeding Episodes by Nearly 90%

Emicizumab is administered subcutaneously only once per week compared with clotting factors administered intravenously 3 times per week. Read more...

4. Orencia Receives FDA Approval for Psoriatic Arthritis

Abatacept (Orencia) receives approval for third autoimmune condition. Read more...

3. FDA Approves First Sickle Cell Disease Drug in Nearly 20 Years

The approval greatly expands treatment options for rare inherited blood disorder. Read more...

2. Biosimilar Uptake Challenges: Low-Cost Specialty Drugs Reduce Provider Profits

Study finds the current reimbursement model for biosimilars needs to be adjusted to improve uptake. Read more...

1. Challenges for Launching Biosimilar Products

The ability of manufacturers to convey the efficacy and safety of a new biosimilar is crucial. Read more...